HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beiersdorf

This article was originally published in The Rose Sheet

Executive Summary

Firm is advertising its Nivea Visage brand on TV for the first time in the U.S. with a 30-second ad for the line's Anti-Wrinkle Creme airing in Boston, Chicago, Miami and New York over the next six weeks. The ad, which will roll out to additional U.S. markets in the fall, asks consumers if they are "Worried about Wrinkles?" The ad suggests: "Then use the creme found by a leading French consumer publication to be the most effective and one of the least expensive. Yes, that's right, Nivea Visage Anti-Wrinkle Creme." TBWA, New York designed the campaign. The TV ads, which are tagged with a local retailer in each market, also inform consumers about a concurrent sweepstakes promotion. Beiersdorf said it is considering advertising other Nivea Visage products on TV and plans to continue its ongoing print campaign for the brand

Latest Headlines
See All
UsernamePublicRestriction

Register

RS000383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel